• Home
  • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Fortune 500
    • Fortune 500 U.S.
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
  • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  • Home
  • Latest
    • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Fortune 500
    • Fortune 500
    • Fortune 500 U.S.
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
  • Finance
    • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  1. home
  1. home
  2. biogen

biogen

Page 4 of 4

Novo Nordisk Chief Executive Officer Lars Soerensen Interview
Leadership

This Big Pharma Chief Was Just Named the World’s ‘Best-Performing’ CEO—Again

By Sy Mukherjee
October 12, 2016
Biogen Drug Shows Early Promise against Alzheimer’s Disease
Tech

Biogen Drug Shows Early Promise against Alzheimer’s Disease

By David Z. Morris
September 3, 2016
George Scangos, CEO of Biogen Inc. speaks during Reuters Health Summit in New York
Health

Biogen Shares Are Spiking On Rumors of a Mega-Deal With Its Rivals

By Sy Mukherjee
August 2, 2016
Whistleblower Claims Celgene Colluded With Charities to Drive Profits
Health

Whistleblower Claims Celgene Colluded With Charities to Drive Profits

By Sy Mukherjee
August 1, 2016
483106863
Health

Drug Companies Really Don’t Care About the Price Hike Backlash

By Sy Mukherjee
July 14, 2016
Could a Molecular ‘On-Off Switch for Agony’ Lead to a Safer Painkiller?

Could a Molecular ‘On-Off Switch for Agony’ Lead to a Safer Painkiller?

By Damian Garde and STAT News
July 7, 2016
How Medical Researchers Are Breaking the Blood-Brain Barrier
Health

How Medical Researchers Are Breaking the Blood-Brain Barrier

By Erika Fry
June 28, 2016
Samsung Holds Shareholders Meeting
Tech

Samsung Has a Best-Selling American Drug in Its Crosshairs

By Sy Mukherjee
May 24, 2016
Drugs From European Pharmaceuticals Companies As Stocks Outperformed The Stoxx 600 Index By 1.2 percentage Points
Finance

Biotech Stocks Are Down 25% So Far This Year

By Sy Mukherjee
May 6, 2016
Stocks Close Sharply Lower As Oil Prices Continue Decline
Finance

These Biopharma Companies Are the World’s Top Shareholder Value Creators

By Sy Mukherjee
May 3, 2016
Biogen to Fire Workers, Restructure R&D After Difficult Year
Health

Why Biogen Is Spinning Off its Hemophilia Drug Business

By Reuters
May 3, 2016
547016547
Health

Why Biogen Is Poaching This Pfizer Exec to Head Up Its R&D Shop

By Sy Mukherjee
April 27, 2016
Trading On The Floor Of The NYSE As U.S. Stocks Rise With Oil After Best Weekly Gain Since November
Finance

Here’s Why Biogen’s Shares Are Climbing Today

By Sy Mukherjee
April 21, 2016
The CEO of Valeant Pharmaceuticals has suggested that Allergan is fat, overstaffed and ripe for big
Health

Allergan Struck a $3.3 Billion Alzheimer’s Drug Deal Right After Its Pfizer Merger Collapsed

By Sy Mukherjee
April 7, 2016
Light snow falls on the Dow Chemical Co. Michigan Operations
Leadership

Bathroom Battle Draws in Big Business

By Alan Murray
March 25, 2016

Most Popular

  • Economy
    The $38 trillion national debt is to blame for over $1 trillion in annual interest payments from here on out, CRFB says
    By Nick Lichtenberg
  • AI
    Meta’s 28-year-old billionaire prodigy says the next Bill Gates will be a 13-year-old who is ‘vibe coding’ right now
    By Eva Roytburg
  • Success
    As graduates face a ‘jobpocalypse,’ Goldman Sachs exec tells Gen Z they need to know their commercial impact 
    By Preston Fore
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Fortune
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.